MONITORAMENTO E AVALIAÇÃO DA TOXICIDADE HEMATOLÓGICA RELACIONADA À QUIMIOTERAPIA EM PACIENTES COM CÂNCER COLORRETAL
MONITORAMENTO E AVALIAÇÃO DA TOXICIDADE HEMATOLÓGICA RELACIONADA À QUIMIOTERAPIA EM PACIENTES COM CÂNCER COLORRETAL
-
DOI: https://doi.org/10.22533/at.ed.3522410041
-
Palavras-chave: Neoplasias colorretais; Antineoplásicos; Toxicidade; Hematologia; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos.
-
Keywords: Colorectal neoplasm; Chemotherapy; Toxicity; Hematology; Drug- Related Side Effects and Adverse Reactions.
-
Abstract: Colorectal cancer is a neoplasm that affects the segments of the large intestine. Treatment depends on the size, location, extension and general condition of the patient, chemotherapy being one of the modalities used. Chemotherapy drugs can generate a series of toxicities, with hematological toxicity being one of the most common and fatal. The study aims to identify the occurrence of hematological toxicity related to the administration of chemotherapy in patients diagnosed with colorectal cancer. In addition to identifying the profile of patients; survey the chemotherapy protocols used in the treatment of colorectal cancer; and understand the impact of hematologic toxicity. This is a descriptive, longitudinal and retrospective study. The sample consisted of patients with colorectal cancer who started outpatient chemotherapy treatment between January and December 2020. For data collection, a patient characterization form and monitoring the results of laboratory tests were created. The analysis was performed descriptively with the variables presented through frequencies and proportions, using Pearson's chi-square test x2 and Fisher's exact test. Ethical principles in research with human beings were respected. The final sample consisted of 145 patients. Regarding the profile, there was a predominance of males (52.4%), with the aged between 60 and 69 years (31.7%) and consuming alcohol, tobacco or both (51%). The most prevalent diagnosis was colon adenocarcinoma (52.4%), with 40% of cases already diagnosed in stage IV. Hematological toxicity was present in 44 patients (30.3%), with thrombocytopenia being found more frequently (56.8%). Regarding the protocols, patients who used XELOX and MFLOX had a greater chance of developing hematological toxicity. Due to toxicity, there was a delay in the administration of the next cycle (38.6%), combined with a reduction in the dose (22.7%), with a change of protocol or suspension of chemotherapy in 9% of cases.
- Davi da Silva Nascimento
- Débora Cristina Aleixo Lara
- Jéssica dos Santos Guedes
- Kamila Rocha Fernandes Lima
- Karisia Karen Ricarte Lô
- Isabella Mayara Cleide Diana Mariana Nepomuceno de Souza